Novartis India: ChrysCapital completes stake purchase, board appoints new MD and CEO

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1600.00

prior close

₹1610.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.6-0.4-0.7-0.3

Next day

-2.4+0.5-2.9-0.5-1.9

+2.8+1.9+0.9+0.2+2.6

+1.8+2.3-0.5+0.1+1.7

+2.3+3.6-1.4+0.5+1.8

-0.1+4.0-4.1+0.7-0.8

+0.2+4.0-3.7+1.4-1.2

15d

-7.3+4.9-12.2+0.4-7.7

-1.6+5.9-7.5+1.7-3.3

+19.7+4.8+14.9+2.7+17.0

+7.8pendingpending-3.1+10.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sale of 17,450,680 equity shares from Novartis AG to ChrysCapital entities completed today, changing control of Novartis India. Board approved Tegrital brand license, 5-year distribution deal with Novartis Pharma Services AG, and assignment of Voveran, Macalvit and Citromacalvit trademarks. Dr. Vikas Gupta appointed MD and CEO; Bhagwat Singh Deora as CFO. New website nilpharma.co.in adopted under new management. Board committees reconstituted.

Likely market impact

Control shifts to ChrysCapital. Business continuity secured through Novartis distribution and brand pacts. Stock may re-rate under new management.